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Abstract
Permanent damage to white matter tracts, comprising axons and myelinating oligodendrocytes, is 
an important component of newborn brain injuries that cause cerebral palsy and cognitive 
disabilities as well as multiple sclerosis (MS) in adults. However, regulatory factors relevant in 
human developmental myelin disorders and in myelin regeneration are unclear. Here, we report 
expression of AXIN2 in immature oligodendrocyte progenitor cells (OLP) within white matter 
lesions of human newborns with neonatal hypoxic-ischemic and gliotic brain damage, as well as 
active MS lesions in adults. Axin2 is a target of Wnt transcriptional activation that feeds back 
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negatively on the pathway, promoting β-catenin degradation. We show Axin2 function is essential 
for normal kinetics of remyelination. Small molecule inhibitor XAV939, which targets enzymatic 
activity of Tankyrase, acts to stabilize Axin2 levels in OLP from brain and spinal cord and 
accelerates their differentiation and myelination after hypoxic and demyelinating injury. Together, 
these findings indicate that Axin2 is an essential regulator of remyelination and that it might serve 
as a pharmacological checkpoint in this process.
Introduction
Oligodendrocytes are the myelinating cells of the central nervous system (CNS) that enable 
formation of myelin and saltatory nerve conduction. In humans, premyelinating 
oligodendrocytes are most abundant at gestational age 23-32 weeks and are thought to be 
selectively vulnerable during injury in the neonatal brain1. Hypoxic ischemic 
encephalopathy (HIE) causes neuronal apoptosis as well as diffuse primary damage to sub-
cortical white matter in the term infant brain, while periventricular leukomalacia (PVL) 
comprises focal injury to white matter tracts as well as diffuse gliotic lesions typically in 
premature infants2. Such diffuse and focal injuries, collectively known as white matter 
injury (WMI) in the newborn brain, can result in cerebral palsy (CP) and cognitive 
disability. Indeed, WMI is the most reliable prognostic indicator of development of severe 
CP in premature infants3. In multiple sclerosis (MS), the most common cause of 
neurological disability in young adults, myelin sheaths are lost through the injury or death of 
mature oligodendrocytes as a result of autoimmune damage4.
In these conditions, myelin sheaths can be regenerated by OLP that are recruited to lesions 
and differentiate in a process called remyelination. Conversely, inhibition of remyelination 
may contribute to ongoing neurological dysfunction, axonal loss and disease progression5,6. 
Although oligodendrocytes are thought to be cellular targets of excitotoxic damage in 
newborn brain injuries2,7, several lines of evidence indicate failure of remyelination as 
contributing to fixed demyelinated lesions8,9. Indeed, both PVL8,9 and MS5,6 lesions show 
presence of non-myelinating OLP.
The molecular mechanisms that might dysregulate myelination in neonatal brain injury are 
unknown. We have previously shown that active Wnt signaling can act to inhibit 
oligodendrocyte OLP differentiation during remyelination in the adult rodent CNS10, and 
several studies show that Wnt activation inhibits developmental myelination10-12. In the 
absence of Wnt ligands, β-catenin levels are regulated through a phosphorylation/
degradation complex13,14 containing glycogen synthase kinase 3β (GSK-3β) and the 
scaffolding proteins, Axis inhibition protein 1 (Axin1), adenomatous polyposis coli (APC) 
and disheveled (Dsh). The presence of Wnt ligand results in stabilization of β-catenin and its 
translocation to the nucleus, where it forms a nucleoprotein complex with Tcf/LEF 
transcription factors to activate or repress expression of target genes15,16. While Axin1 is 
expressed ubiquitously, Axin2/conductin is a transcriptional target of active Wnt signaling 
that also serves to auto-regulate and repress the pathway by promoting β-catenin degradation 
in many different tissues and systems14,17-19. Dual roles for signaling targets that also serve 
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as feedback repressors are seen in other pathways such Sonic hedgehog (Shh), where the 
repressors Patched and Gli3 are activated by Shh20.
We observed expression of AXIN2 mRNA transcripts in situ in OLP in WMI associated with 
neonatal HIE and PVL. Although Axin2 function has been reported as dispensable during 
brain development21, we show that Axin2 function is essential for normal myelination and 
remyelination. Moreover, Axin2 levels can be manipulated pharmacologically in OLP to 
promote accelerated differentiation, suggesting Axin2 serves as a therapeutic target in 
situations where OLP differentiation is delayed or stalled.
Results
AXIN2 mRNA marks OLP in human neonatal white matter injury
We have previously shown Wnt pathway activation using the transgenic Bat-Gal reporter in 
developing OLP in vivo, and that forced activation of the canonical Wnt pathway during 
development of transgenic Olig2-cre X floxed-Dominant-active β-catenin mice inhibits 
differentiation of OLPs to mature oligodendrocytes (OL)10. Expression profiling of P4 
spinal cord from these mice indicated significant downregulation of genes associated with 
OL maturation (Suppl. Tab. 1, Suppl. Fig. 1), including MBP, PLP, CNPase, MOG, MAG, 
Mobp, FA2H, MAL and transcription factor MRF22. This analysis also identified known 
Wnt-activated targets, such as Naked1, Notum and Axin2 as significantly upregulated. In 
contrast, changes in expression of the Wnt pathway antagonist adenomatous polyposis coli 
(APC, also known as CC1) were not significant, indicating that its expression in Olig2-cre X 
floxed-Dominant-active β-catenin mice is uncoupled from OL differentiation.
Using expression of AXIN2 mRNA transcripts to mark Wnt-activated white matter cells in 
situ, we investigated two types of human neonatal brain injury characterized by white matter 
damage and injury to oligodendrocyte lineage cells resulting in hypomyelination (Suppl. 
Fig.2). As shown, (Fig. 1a, b, c), we observed AXIN2 mRNA expression solely in Olig2-
positive cells within affected white matter in neonatal HIE and PVL (Note, in PVL staining 
localized adjacent to the cystic core of lesion) but not white matter in age-matched controls 
(Fig. 1a, c). Within the HIE cases, AXIN2 mRNA was expressed in a subset of the Tcf4 
positive cells (Fig. 1d), consistent with activation of canonical Wnt signaling. AXIN2 mRNA 
segregated from the mature OL marker PLP in situ (Fig. 1e), and segregated completely 
from GFAP (Fig. 1f). Similarly, the independent Wnt activated target Naked1 (Nkd1) was 
expressed in PDGFRα-positive OLP, but not astroglia (Fig. 1g, h, Suppl. Fig. 3). The 
expression of these Wnt targets provides strong evidence that the Wnt pathway is activated 
specifically in immature, pre-myelinating OLPs in human neonatal white matter injury 
(Suppl. Fig. 4). We thus, went on to address possible functions of Axin2 in OLP in animal 
models.
Axin2 function is required for OLP differentiation
Whilst Axin2 mRNA serves as a marker for pathway activation, Axin2 protein functions as a 
negative feedback mechanism to control activation of the Wnt pathway via β-catenin 
degradation17,18. Using wild type and Axin2-lacZ heterozygous mice18 we characterized 
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Axin2 mRNA and reporter gene expression during developmental myelination (Fig. 2a-d). 
Axin2 mRNA is expressed in immature Nkx2-2+ OLP but not CC1+ differentiated OL (Fig. 
2b). In contrast, reporter β-galactosidase proteins are first detectable at the later CC1+ stage 
(Fig. 2c, d; Suppl. Fig. 6).
Axin2-lacZ homozygous null animals showed a significant delay in OLP differentiation 
during developmental myelination (Fig. 2e, f; Suppl. Fig. 7). Moreover, as indicated by co-
expression of β-galactosidase with PDGFRα (Fig. 2g), the reduction in mature OL number 
reflects delay in OLP maturation, rather than decreased OLP numbers. Indeed, there is no 
difference in apoptosis or proliferation of the OLP pool (Suppl. Fig. 8). We also observed a 
significant (p < 0.005) impairment of Axin2−/− OL differentiation in vitro (Fig. 2h, i), and 
strong activation of the independent Wnt target Notum (Fig. 2j). Thus, Axin1 is unable to 
compensate for the loss of early Axin2 functions in OL differentiation in vitro or in vivo.
Axin2 is expressed in MS and functions in myelin repair
Previous studies indicate that lesions of both neonatal PVL and adult MS show OLP, 
evidently ‘stalled’ in their differentiation5,6,8,9, which has been proposed to result in 
defective repair and fixed demyelinated lesions23. Thus, we focused on regulatory functions 
of Axin2 in the context of primary damage to oligodendrocytes. We confirmed that AXIN2 
mRNA transcripts are expressed in OLP in active MS lesions (Fig. 3a, b), in which OL are 
targeted for autoimmune attack. Axin2 mRNA expressing cells were not seen in areas of 
normal appearing white matter (NAWM), nor in chronic silent plaques (Fig. 3a). A similar 
pattern of expression was seen for the independent Wnt activated target Naked1 (Nkd1). 
Naked1 protein expressing cells were seen at active MS lesion edges (Fig. 3c, Suppl. Fig. 5), 
with the simple bipolar morphology characteristic of OLP (Fig. 3c), and at a similar cellular 
density to Axin2 mRNA expressing cells (Fig. 3c). Remyelination can be investigated after 
adult murine lysolecithin injury, which kills resident OL while leaving axons largely intact. 
Such lesions in spinal cord ventral or dorsal white matter have been extensively 
characterized24 and show OLP recruitment (5 days post lesion (dpl)), differentiation (10 dpl) 
and myelination (14 dpl) with stereotyped timing in young adult animals (Fig. 4a), allowing 
precise assessment of remyelination kinetics.
In adult animals, we observed robust expression of the β-gal reporter in Axin2-lacZ 
heterozygote mice 10 days after demyelination (Fig. 4b). Although mature OL numbers 
normalize by 8 weeks of age in Axin2−/− animals (Fig. 4f, Suppl. Fig. 9), Axin2−/− null mice 
showed significantly delayed remyelination compared to WT littermates (Fig. 4c, Suppl. 
Fig. 10), due to a delay in Nkx2.2+ OLP differentiation (with normal OLP recruitment) in 
lesions at 10 and 14 dpl (Fig. 4c-f). The inflammatory cell and astrocyte response in lesions 
was not affected in Axin2−/− mice (Suppl. Fig. 11), demonstrating that the delay in 
remyelination in Axin2 null animals is attributable to a cell-autonomous requirement in OLP.
Axin2 protein stabilization promotes OLP differentiation
We next investigated whether enhanced Axin2 activity might promote accelerated 
oligodendrocyte maturation. Axin2 and Axin1 were recently identified as substrates for the 
poly-ADP-ribosylating enzymes Tankyrase 1 and 225, which promote Axin degradation 
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through the ubiquitin-proteosome pathway. Small molecule XAV939 inhibited tankyrase 
activity in cell lines at 5μM concentration, resulting in stabilized Axin protein levels25.
As shown (Fig 5a, b), Tankyrase is expressed in the rodent OL lineage during development 
commencing at a mature stage, and continues to be expressed in oligodendrocytes in adult 
white matter (S. Fancy and D. Rowitch, unpublished observations). Tankyrase is also 
expressed within early differentiating OLs following demyelination in the adult spinal cord 
white matter of the mouse (Fig. 5c and inset).
Given these findings, we tested effects of XAV939 to stabilize Axin protein levels in OLP in 
vitro. As shown (Fig. 5d), treatment with 0.01 or 0.1μM XAV939 for 24 hours produced 
increases in the levels of both Axin2 and Axin1 proteins in OLP versus vehicle controls, and 
increased protein levels of Tankyrase 1 and 2, presumably due to reduction in their 
autoparsylation and self-induced degradation25. XAV939 treatment of OLP resulted in 
increased levels of phospho-β-catenin and β-catenin degradation, as well as reduced levels of 
Axin2 mRNA transcripts (Fig. 5e) and activity of a transduced Topflash reporter (data not 
shown), indicating inhibition of the Wnt pathway. Moreover, in addition to early effects on 
Wnt pathway per se, XAV939 treatment promoted precocious OL differentiation (Fig. 5f-h), 
as evidenced by increased expression of the mature oligodendrocyte marker myelin basic 
protein (MBP).
We next confirmed Tankyrase protein expression within the human OL lineage during 
neonatal white matter injury. As shown (Fig. 5i), Tankyrase was expressed in later stage OL 
cells that expressed NOGO-A+ and cytoplasmic Olig1+. Conversely, Tankyrase expression 
was not observed in inflammatory macrophages, microglia or reactive astrocytes within 
gliotic areas of white matter damage. These data suggest the potential for pharmacological 
manipulation of Axin2 levels in OLPs through Tankyrase inhibition in human neonatal 
white matter injuries.
To address this question, we investigated XAV939 effects on OLP in mouse cerebellar slice 
cultures (Fig. 6) In this system, slices of P0-P1 neonatal cerebellum are cultured in the 
presence of factors that can affect remyelination26 of cerebellar white matter. We examined 
the ratio of NFH-positive axons that showed co-expression of myelin basic protein (MBP) 
and measured the density of Nodes of Ranvier, indicated by Caspr-positive paranodes, As 
shown (Fig. 6a, a’), 0.01μM XAV939 treatment significantly increased myelination 
compared with controls. Moreover, we observed that acute hypoxic exposure (2% oxygen 
for 24 hrs) reduced myelination to levels significantly below controls (Fig. 6b, a’), We 
suggest the impact of hypoxia in this system is primarily due to inhibition of OLP 
maturation because Nkx2.2-Olig2 double positive OLP numbers were significantly 
increased without detectable reduction in Olig2-positive cells (Fig. 6b’). Treatment with 
XAV939 reversed the impact of hypoxia, and indeed, increased the extent of myelinated 
axons to well above control levels. To demonstrate that XAV939 treatment can act on 
cerebellar OLP to promote remyelination, we also tested its effects after addition of 0.5% 
lysolecithin to culture medium to induce toxic injury to oligodendrocytes (Fig. 6c). In this 
paradigm, XAV939 also promoted a significant enhancement of myelin regeneration (Fig. 
6c’).
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As illustrated above (Fig. 4a), the kinetics of remyelination in vivo in focal toxic injury 
models is tightly regulated and to our knowledge no drugs have been reported that accelerate 
OLP differentiation. To test whether pharmacologic stabilization of Axin might promote 
OLP differentiation during remyelination in vivo, we co-injected young adult (8-10 week 
old) mouse spinal cord lysolecithin lesions with 0.1μM XAV939. As shown (Fig. 7a, c), we 
observed a striking increase in PLP+ differentiated OLs as early as 6 dpl in XAV939-treated 
dorsal and ventral lesions compared to vehicle treated controls. Moreover, such XAV939 
effects are Axin2-dependent, as Axin2 null mice show significantly less OLP differentiation 
at 6dpl following lysolecithin treatment versus controls (Fig. 7b, c). This increase in mature 
OL number at 6 dpl was due to a precocious differentiation of recruited OLP rather than an 
increased survival of existing OL (Fig. 7g). Whilst total Olig2+ cells were similar at 6 dpl in 
XAV939 treated lesions and controls, XAV939 produced a shift in the proportion of Olig2+ 
cells that expressed the mature PLP+ OL versus immature Nkx2.2+ OLP (Fig. 7d, e). 
XAV939 treatment did not affect the inflammatory cell or astrocyte infiltration into lesions 
(Fig. 7f), nor early OLP recruitment into or proliferation within the lesion (Fig. 7h, i). Such 
precocious OLP differentiation in XAV939 treated lesions was associated with significantly 
thicker myelin sheaths (smaller g ratios) compared to controls at 10 dpl when myelin sheath 
formation is on-going (Fig. 7j). Myelin thickness in XAV939-treated remyelinated lesions 
was similar to controls when lesions in both groups are fully remyelinated at 28 dpl (Suppl. 
Fig. 12). These findings indicate that XAV939 treatment significantly accelerates the 
processes of OLP differentiation and compact myelin formation in vivo.
Discussion
Despite advances in neonatal intensive care in developed countries, newborn brain injuries 
such as HIE in full term infants and PVL in very premature infants remain leading causes of 
cerebral palsy and cognitive disability. Indeed, the incidence of these conditions is rising27, 
owing to the increasing survival of extremely low birth weight premature infants born at 
gestational ages <28 weeks. While WMI and demyelination is primary in MS, it is also a 
significant component of HIE and PVL. Progression in MS lesions to a stage of chronic 
demyelination is thought to reflect both autoimmune-mediated damage to oligodendrocytes 
as well as inefficient repair. In both MS5,6 and PVL8,9 there is evidence for ‘stalled’ OL 
precursors that fail to engage in remyelination.
The presence of AXIN2-and Nkd1-positive OLP in neonatal HIE and PVL as well as MS, 
suggests a generalized Wnt pathway activation response in white matter to diverse types 
(both toxic, auto immune and hypoxic) of injury. However, further work is needed to 
confirm this proposal in other human neuropathological conditions (e.g., spinal cord injury). 
Because Axin2 expression serves dual roles as a readout of the Wnt pathway and a feedback 
inhibitor, the presence of Axin2+ OLP likely signifies cells attempting to myelinate axons. 
Our studies show Axin2 to be a potent regulator of the timing of remyelination, an important 
determinant of effective repair and functional recovery in human MS and animal models28. 
Several lines of evidence indicate that the Wnt pathway acts cell autonomously in OLP. 
First, we have previously activated β-catenin within OLP in vivo and observed delayed 
differentiation10. Second, dispersed cultures of Axin2−/− OLP showed delayed 
Fancy et al. Page 6
Nat Neurosci. Author manuscript; available in PMC 2012 February 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
differentiation, and third, wild type OLP cultures treated with XAV939 show accelerated 
differentiation (Suppl. Fig. 13).
It is unclear whether the effect of dysregulated Wnt signaling is sufficient to account for 
stalled OLP maturation, or as more likely, that Wnt signals are amongst several factors that 
may be involved. The abnormal environment of a demyelinated axon tract, containing 
inflammatory cells, myelin debris29 and other factors (e.g., Lingo-130, Notch31 signaling), 
appear to also inhibit remyelination. Delayed remyelination kinetics might lead to chronic 
demyelination23, in keeping with recent studies showing that oligodendrocytes initiate new 
myelin segments only during a temporally restricted developmental window32.
Despite probably complex roles of multiple factors in remyelination, treatment with 
XAV939 alone was sufficient to stabilize Axin proteins and promote dramatically 
accelerated oligodendrocyte differentiation after demyelinating injury. Our data in Axin2−/− 
animals demonstrate that XAV939 acts specifically through its effects on Axin2, and our in 
vitro studies indicate that this acts to inhibit the canonical Wnt pathway through β-catenin 
phosphorylation/degradation. XAV939 was non-toxic to OLP at early stages of recruitment 
and proliferation and acted to accelerate differentiation and formation of compact myelin. 
These findings indicate that Wnt pathway activity is dispensable for myelin regeneration.
Our therapeutic approach employed targeted injection of XAV939 into spinal cord lesions. 
Although this approach might seem to present technical challenges, we note that non-
invasive imaging currently allows for precise neurosurgical placement of devices, neural 
progenitor cells and drugs directly into white matter tracts of the brain. In preliminary 
studies, we observe upregulation of Tcf4, Axin2, Nkd1 and Notum in the white matter of 
neonatal mice exposed to chronic hypoxia, and that Axin2−/− animals sustain permanent 
deficits in white matter after such injury (J. Silbereis, E. Harrington, S. Fancy and D. 
Rowitch, unpublished observations). XAV939 treatment promoted robust myelination of 
axons after cerebellar cultures were exposed to hypoxia, suggesting efficacy of XAV939 to 
act on OLP from the brain to promote myelination after a developmental hypoxic insult. 
Further study of systemic XAV939 (and similar agents that stabilize Axin2) administration 
is needed to determine possible toxicity and efficacy in promoting remyelination in pre-
clinical models of human neonatal hypoxic white matter injury and adult demyelinating 
diseases33.
Methods
Transgenic Mice and procedures
Animal husbandry and procedures were performed according to UCSF guidelines under 
IACUC approved protocols.
Axin2-LacZ—The Axin2-LacZ mouse has been described previously (Lustig, B, et al. Mol 
Cell Biol 22:1184–1193 (2002)). Insertion of β-galactosidase gene into Axin2 locus (Axin2-
LacZ) provides a useful tool for visualizing cells that are actively responding to Wnt in vivo. 
LacZ insert mimics the expression pattern of Axin2 but does not lead to detectable 
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phenotype in heterozygous state. In homozygous state, this effectively acts as an Axin2 null 
animal.
Olig2-tva-cre—A multi-functional mouse line was constructed previously (Schüller, U, et 
al. Cancer Cell 14:123-134 (2008)). Olig2-cre allowed for cre mediated activity in 
oligodendrocyte lineage cells.
DA-Cat—The DA-Cat mouse was produced previously (Harada, N, et al. EMBO J. 18(21):
5931-5942 (1999)) and has exon 3 of mouse β-catenin gene located between loxP sequences. 
Cre recombinase mediated deletion of exon 3 produces dominant stable mutant β-catenin 
protein.
Induction of demyelination with lysolecithin in mouse spinal cord
Demyelinated lesions were produced in ventrolateral spinal cord white matter of 8-10 week 
old Axin2 null and wild-type littermate mice. The method has been described previously 
(Fancy, SPJ, et al. Genes and Development 23, 1571-1585 (2009)). Animals were 
euthanased at three survival time points: 5 days post lesion (dpl), representing peak OLP 
recruitment, 10 dpl representing onset of OLP differentiation and 14 dpl representing new 
myelin sheath formation (n=4 for each survival time).
Immunohistochemistry
The method has been described previously (Fancy, SPJ, et al. Genes and Development 23, 
1571-1585 (2009)). The primary antibodies were: Tcf4 (mouse monoclonal 6H5-3, Upstate), 
Olig2 (rabbit polyclonal from CD Stiles, Harvard), Nkx2.2 (mouse monoclonal, 
Developmental Studies Hybridoma Bank), PDGFRα (rat 558774, BD Biosciences), APC 
(CC1)(mouse monoclonal OP80, Calbiochem), NOGO-A (rabbit, Millipore), β-gal (rabbit 
55976, MP), Tankyrase (mouse monoclonal 19A449, Abcam), Iba1 (rabbit, Wako), CD3 
(rabbit, Dako), GFAP (mouse, Sigma), Naked1 (rabbit, Cell Signaling Technology) and 
Notum (rabbit, Abcam). Secondary fluorescent antibodies from Alexa were used.
Cell counts and statistical measures
For all cell counts, at least four animals per genotype were used for each time point 
indicated. Cells were counted on three or more non-adjacent sections per mouse and 
presented as an average +/− standard deviation. Statistical comparisons of cell counts were 
established using Student t test.
Human MS tissue
Human post-mortem tissue blocks were provided by the UK Multiple Sclerosis Tissue Bank 
at Imperial College London. All tissues were collected following fully informed consent by 
the donors via a prospective donor scheme following ethical approval by the London 
Multicentre Research Ethics committee (MREC 02/2/39). MS lesions were characterized 
according to Lock et al. Nat. Med. 8: 500-508 (2002), using Luxol Fast Blue to assess 
demyelination, SMI-31 immunohistochemistry to assess preservation of axons, and LN3 
immunohistochemistry to assess inflammatory cell activity. Lesions with florid parenchymal 
and perivascular inflammatory cell infiltration, myelin fragmentation, and demyelination 
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with indistinct margins were classified as active plaques (AP). Chronic active plaques (CAP) 
were classified as those with extensive demyelination well demarcated borders and abundant 
inflammatory cells at the lesion edge. Chronic plaques (CP) were classified as those with 
extensive demyelination, well demarcated borders but few or no inflammatory cells in any 
part of the demyelinated area.
Human Developmental Tissue
All human tissue was collected in accordance with guidelines established by the University 
of California San Francisco Committee on Human Research (H11170-19113-07). 
Immediately after procurement, all brains, except Case 1, were immersed in 4% phosphate 
buffered formalin for one week at room temperature. In Case 1, the brain was immersed in 
phosphate buffered saline with 4% paraformaldehyde for three days. On day 3, brains were 
cut in coronal plane at level of Mamillary Body and immersed in fresh 4% 
paraformaldehyde/PBS for additional three days. Post fixation, all tissue samples were 
equilibrated in PBS with 30% sucrose for at least 2 days, before OCT embedding. The 
diagnosis of hypoxic ischemic encephalopathy (HIE) requires clinical and pathological 
correlations. With respect to the pathological features, all HIE cases in study showed 
consistent evidence of diffuse white matter injury, including astrogliosis and macrophage 
infiltration. These findings were confirmed by increase in number and staining intensity of 
GFAP- or CD68-positive cells, respectively. The HIE cases also showed evidence of 
neuronal injury, including presence of ischemic neurons and variable degrees of neuronal 
loss, in cerebral cortex, hippocampus and basal ganglia. Representative images in 
Supplementary Figure 2 show GFAP immunoreactivity most intense in the Layer 1 of 
cerebral cortex and in the subcortical white matter.
Case 1, 2, 3, 4 and 5 demonstrated clinical evidence of HIE and pathological evidence of 
HIE and low output state in multiple organs on post-mortem examination. More specific 
findings in Case 1 (8 week-old, born at full term) included hypoplastic left heart status-post 
procedure and diffuse white matter injury in brain with focal neuron dropout in cerebral and 
cerebellar cortices. Case 2 (five-day old, born full term) with a clinical diagnosis of severe 
HIE who underwent therapeutic hypothermia showed diffuse white matter injury on post-
mortem evaluation. Case 3 (five month old, born preterm at 26 weeks gestation) clinically 
showed failure to thrive, enterocolitis, hypoxemia and ventriculomegaly. Decreased 
myelination relative to the patient’s age, diffuse white matter gliosis, and focal loss of 
cortical neurons were noted in this patient. Case 4 (6 day old male born at 35 and 5/7 weeks) 
with in utero polyhydramnios showed neuropathological findings of hypoxic ischemic 
encephalopathy and intraventricular hemorrhage. Case 5 (6 day old female born at 37 and 
4/7 weeks) with intrauterine growth retardation showed hypoxic ischemic encephalopathy 
characterized by widespread neuronal death in the putamen, thalamus, hippocampus, diffuse 
hypoxic white matter changes, and diffuse cerebral edema. Case 6 (12 week old, born at 35 
3/7 weeks) with congenital diaphragmatic hernia, hypoplastic heart, and coarctation of aortic 
arch showed periventricular leukomalacia adjacent to the lateral ventrical. Case 7 (one-day 
old term infant) with midgut volvulus with extensive hemorrhagic necrosis of small bowel 
was not found to have significant neuropathological findings of HIE. Case 8 (1 day old 
female, born at 37 weeks) with hypoplastic left heart complex died shortly after birth and 
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showed no evidence of white matter damage. Case 9 (four month old male born at 38 5/7 
weeks) with congenital diaphragmatic hernia and hypoplastic aortic arch status post 
procedure was complicated by uncontrolled respiratory syncytial virus (RSV) pneumonia. 
Neuropathological evaluation of case 9 did not show diffuse white matter injury.
In vitro Oligodendrocyte Progenitor cell culture
OLPs were isolated by immunopanning postnatal day 7 CD-1 mouse cerebral cortices as 
previously described (Emery, B, et al. Cell 138(1): 172-185 (2009); Harrington, E, et al. Ann 
Neurol 68:703-16 (2010)). OLPs were plated on poly-D-lysine coated plates and coverslips 
and maintained in proliferation media in a 10% CO2 37°C incubator with 50% media 
changes every two days. Proliferation media has been described previously (Harrington, E, 
et al. Ann Neurol 68:703-16 (2010)). For differentiation, OPC proliferation media was 
replaced with differentiation media: OPC mitogens in proliferation media replaced with 
CNTF (10ng/ml) and T3 (40ng/ml).
XAV939 treatment of OLP cultures and differentiation assays
After immunopanning OLPs were plated at a density of 5,000 cells/coverslip in proliferation 
media and allowed to recover for 24 hours. XAV939 (Tocris) or DMSO was added to media 
for 24 hours. Differentiation was induced by replacement of media with differentiation 
media including pre-treatment XAV939 concentration or DMSO. For westerns OPCs were 
plated at a density of 0.5×106 cells/15cm plate and maintained until 75% confluent ~4 days. 
XAV939 or DMSO was added to media for indicated time period. For differentiation, cell 
counts of at least 3 coverslips and 3 separate experiments (n=9 and n=300-1000 cells for 
each test group) were imaged and counted. Comparison of means between two groups were 
analyzed with unpaired T-test and statistical significance was set at p<0.01.
Western Blot of OLP
Western blot was performed as previously described (Harrington, E, et al. Ann Neurol 
68:703-16 (2010)). The primary antibodies were: beta-actin 1:5000 (Cell Signaling 4970), 
axin1 1:250 (Cell Signaling 2087), axin2 1:250 (Cell Signaling 2151), phospho-beta catenin 
1:1000 (Cell Signaling 9561), tankyrase 1:1000 (Abcam ab13587), MBP 1:10,000 
(Sternberger SMI-94).
XAV939 treatment in vivo in mouse spinal cord demyelination model
XAV939 (Tocris) was dissolved in DMSO to a concentration of 10mM, then diluted in 
sterile water to a concentration of 10μM. This stock was then added to 1% lysolecithin 
immediately before lesioning to a final concentration of 0.1μM XAV939. DMSO alone was 
added for control animals. Wild-type young adult mice (8-10 week old) were then co-
injected with the mixture in dorsal or ventral funiculus spinal cord white matter as described 
above, and harvested at the times described post lesioning.
Expression profiling of Olig2cre/DA-cat vs WT spinal cord at P4
Whole spinal cords were harvested, homogenized in Trizol and then RNA was extracted 
using RNeasy kit (Qiagen). Microarray analysis was performed at the Genetics Core 
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Facility, Gladstone Institute, San Francisco. For each of P4 WT and Olig2cre/DA-cat, RNA 
from three animals was pooled for use in each array chip, and three Affymetrix Mouse 
Genome 430 2.0 chips were run for each group, for a total of 9 animals for each group of 
WT and Olig2cre/DA-cat.
Ex vivo cerebellar slice cultures
Following decapitation, the brains of newborn CD1 wild-type mice (postnatal day 0-1) were 
dissected out into cold MEM (MEM supplemented with penicillin/streptomycin, Invitrogen) 
and L-Glutamine (4mM). Excess tissue was trimmed around the brain, ensuring that the 
cerebellum remained attached to the underlying piece of hindbrain. Using a McIlwain tissue 
chopper, 350μm sagittal slices of the cerebellum were cut and plated on Millicell-CM™ 
organotypic culture inserts (Millipore, 0.4μm) in slice culture medium containing 50% 
MEM with Earle’s salts, 35% Earle’s balanced salt solution, 25% heat-inactivated horse 
serum, glutamax, fungizone, penicillin-streptomycin (each from Invitrogen), and glucose 
(Sigma).
For the myelinating slice cultures, XAV or DMSO was added at the time of plating. Cultures 
were maintained at 37°C and 7.5% CO2. Membranes were transferred into fresh medium 
supplemented with tested factors every two days. The hypoxic slice cultures were exposed 
to 2% O2 conditions for 24h between 2-3 days in culture and then returned to normal culture 
conditions. XAV or DMSO was added following hypoxia exposure. Both the myelinating 
and hypoxic slices were fixed at 12 days in vitro. Remyelinating slice cultures were adapted 
from previous described methods (Birgbauer et al., 2004). After culturing slices in medium 
with no factors added for 14 days, demyelination was induced by the addition of 0.5% 
lysolecithin (Sigma) to the slice culture medium for 18 hours. Following demyelination, 
slices were then transferred to medium containing XAV or DMSO and maintained for an 
additional 14 days to allow remyelination to occur.
Immunostaining of slice cultures
Slices were immersed in 4%PFA for 1h while attached to membranes at the desired 
timepoints. Slices were then rinsed in PBS, blocked with 3% heat-inactivated horse serum, 
2% bovine serum albumin, and 0.25% Triton X-100 in PBS, then incubated overnight at 4°C 
in primary antibody diluted in block solution. Primary antibodies were: chicken polyclonal 
anti-neurofilament 200kDa (NFH, Encor Biotech), rat monoclonal anti-MBP (Serotec), and 
rabbit polyclonal anti-Caspr (AbCam, 1:500).
Slice Culture imaging and quantification
Confocal z-stacks were acquired (12 slices) using Leica SP5 confocal microscope. Upon 
examination of staining, sections were chosen based on their intact cytoarchitechture and the 
formation of parallel myelinated tracts in the cerebellum. Any slices that did not meet these 
criteria were not analyzed. Imaging was focused on the areas of the cerebellum that 
contained parallel tracts of myelinated axons. Obtained images were processed and analyzed 
using the public domain NIH Image program (developed at the U.S. National Institutes of 
Health and available on Internet at http://rsb.info.nih.gov/nih-image/). Following 
compression of images into one z-stack, NIH Image was used to threshold area of staining 
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for Caspr and NFH. Myelination was then quantified by a ratio of percent area stained for 
Caspr to percent area stained for NFH. All imaging and subsequent data analysis was done 
blinded to conditions being tested. Three independent experiments were conducted and 
analyzed. The data were analyzed by one-way ANOVA with Dunnett’s multiple comparison 
test (GraphPad Prism).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. AXIN2 mRNA expression identifies Wnt pathway activation in immature 
oligodendrocytes within neonatal human white matter injury
(a) AXIN2 mRNA is expressed in areas of affected subcortical white matter in human 
pediatric cases of Hypoxic ischemic encephalopathy (HIE) and also adjacent to the cystic 
core of a periventricular lesion of Periventricular Leukomalacia (PVL), but is not seen in 
age-matched controls.
(b) AXIN2 mRNA is expressed solely in Olig2-positive cells within affected white matter in 
neonatal HIE.
(c) Quantification of the number of AXIN2 mRNA expressing cells in areas of white matter 
from HIE cases and control subjects.
(d) In the HIE cases, AXIN2 mRNA was expressed in a subset of the Tcf4 positive cells, 
which (e) segregated from the mature OL marker PLP in situ.
(f) AXIN2 mRNA expression in HIE separates completely from cells expressing GFAP 
proteins.
(g)(h) The independent Wnt activated target Naked1 (Nkd1) is upregulated in neonatal HIE; 
proteins are expressed cytoplasmically in OLP expressing PDGFRα(h), but separate 
completely from cells expressing GFAP proteins (g).
Scale bar in all = 10μm.
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Figure 2. Axin2 functions as a negative regulator of Wnt signaling in OLPs and promotes 
differentiation
(a) Schematic for Axin2 mRNA expression in WT mice and β-catenin/Tcf4-driven reporter 
expression in heterozygous Axin2-lacZ mice.
(b) During developmental myelination of corpus callosum (CC), Axin2 mRNA is confined to 
earlier stage immature OLP that express Nkx2.2 protein, but separates from mature OL 
expressing APC (CC1) protein.
(c, d) Using Axin2-lacZ heterozygous mice during developmental myelination, β-
galactosidase proteins were first detectable at a stage of the OL lineage in P9 corpus 
callosum that express mature marker APC (CC1), but separated from OLP markers 
PDGFRα (c) and Nkx2.2 (d), suggesting that kinetics of reporter expression lags behind that 
of Axin2 mRNA during developmental myelination. Tcf4 expression was observed in only a 
subset of β-gal+ cells (d). Scale bar in b, c, d = 10μm.
(e) Axin2-lacZ homozygous null animals demonstrated a significant reduction in mature OL 
expressing PLP mRNA (and MBP protein, inset) at P9 during developmental myelination of 
the corpus callosum, despite normal numbers of OLP expressing Nkx2.2 protein. Scale bar = 
600μm (100μm in MBP inset; 15μm in Nkx2.2 inset).
(f) Quantification during developmental myelination of the reduced (t test p=0.007) mature 
PLP-expressing OL in P9 Axin2 null corpus callosum (black bars) compared to 
heterozygous littermates (grey bars), despite normal numbers of Nkx2.2-expressing OLP.
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(g) Whilst β-gal expression separates from OLP markers in Axin2-lacZ heterozygotes (Fig. 
2c, d), overlap of β-gal with PDGFRα is observed in Axin2−/− animals as OLP are delayed in 
their differentiation.
(h, i) There is a marked impairment of Axin2−/− OL differentiation in vitro as evidenced by a 
significant (t test p < 0.005) reduction in the percentage of Olig2+ cells expressing MBP at 
60 hours post differentiation in culture. Scale bar in h = 25μm.
(j) There is a strong activation of the independent Wnt target Notum mRNA in Axin2−/− 
OLP cultures compared to WT, demonstrating that loss of Axin2 leads to an increase in Wnt 
pathway activity within these cultures.
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Figure 3. AXIN2 is expressed in OLP in active MS lesions
(a) MS lesions were characterized according to Lock et al. Nat. Med. 8: 500-508 (2002), 
using Luxol Fast Blue (LFB) to assess demyelination and LN3 immunohistochemistry to 
assess inflammatory cell activity. AXIN2 mRNA is expressed in cells in active multiple 
sclerosis (MS) lesions, but not within normal appearing white matter (NAWM) or chronic 
plaques. Scale bar in a = 100μm.
(b) AXIN2 mRNA expression within active MS lesions is specific to OL lineage, where it 
co-localizes with Olig2 proteins.
(c) The independent Wnt activated target Naked1 (Nkd1) is also upregulated in active MS 
lesions (Suppl. Fig. 5). Nkd1 proteins are expressed in the cytoplasm of OLP with 
characteristic simple bipolar morphology. The density of cells expressing Nkd1 proteins in 
active MS lesions is similar to the density of cells expressing AXIN2 mRNAs. Scale bar in b, 
c = 10μm.
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Figure 4. Axin2 function is essential for timely myelin repair
(a) Schematic showing use of adult murine lysolecithin injury for investigating 
remyelination kinetics. Such lesions in spinal cord show OLP recruitment (5 days post 
lesion (dpl)), differentiation (10 dpl) and myelination (14 dpl) with stereotyped timing in 
young adult animals, allowing precise assessment of remyelination kinetics.
(b) Following demyelination of adult Axin2-lacZ heterozygote animals with lysolecithin in 
the spinal cord, β-gal proteins are observed within the lesion in mature OL (co-expressing 
APC) at 10 days post-lesioning (dpl), but separate from OLP marker Nkx2.2. Scale bar in b 
low power lesion = 80μm; in high power = 10μm.
(c) Axin2−/− mice showed delayed repair compared to WT littermates. This was due to a 
reduced (t test p=0.03 at 10dpl, p=0.02 at 14dpl) OLP differentiation into mature OL 
expressing PLP mRNA in lesions at 10dpl, despite a normal recruitment of Nkx2.2-
expressing OLP into lesions. Scale bar in c = 80μm.
(d) OLP with dysregulated Wnt signaling in Axin2 null (Axin2-lacZ homozygote) mice at 
10dpl following demyelination showed abnormal kinetics of mature marker acquisition, β-
gal proteins co-localizing with OLP marker Nkx2.2, in contrast to Axin2-lacZ heterozygote 
mice above (b). Scale bar in d = 10μm.
(e, f) Quantification of (e) mature OL (expressing PLP mRNA) and (f) OLP (expressing 
Nkx2.2 protein) in unlesioned and 5dpl, 10dpl and 14dpl demyelinated spinal cord of Axin2 
null animals (black bars) and WT littermates (grey bars).
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Figure 5. Axin protein stabilization through small molecule Tankyrase inhibition promotes OLP 
differentiation in vitro
(a) Tankyrase proteins are detected in the cytoplasm of mouse Olig2+ cells, separating from 
the PDGFRα+ (OLP) stage, at P9 during developmental myelination in the spinal cord (SC).
(b) The onset of Tankyrase expression coincided with expression of β-galactosidase in 
Axin2-lacZ heterozygous reporter mice, at approximately the CC1+ stage of OL 
development.
(c) Tankyrase is also expressed within OL lineage at 10dpl following demyelination with 
lysolecithin in the adult spinal cord white matter of the mouse, co-localizing with mature 
oligodendrocyte marker cytoplasmic Olig1 (inset). Scale bar in a, b, c = 10μm.
(d) XAV939 treatment of mouse OLPs in vitro with 0.01 or 0.1 μM for 24 hours produced 
marked increases in the protein levels of both Axin2 and Axin1 versus vehicle controls, 
leading to an increased activity of the β-catenin degradation complex, evidenced by an 
increase in degraded phospho-β-catenin protein levels.
(e) At 0.01 μM, XAV939 treatment effectively inhibited the Wnt pathway in OLP in vitro 
after 96 hours, evidenced by a reduction in mRNA levels of the Wnt target Axin2.
(f, h) In vitro OLP differentiation assays demonstrate a significant increase in the proportion 
of Olig2+ cells expressing mature OL marker MBP in the presence of either 0.1 or 0.01 μM 
XAV939 at both 48 and 60 hours post-differentiation compared to vehicle control treatment. 
Scale bar in f = 40μm.
(g) At 60 hours post differentiation of OLP in vitro in the presence of 0.01 μM XAV939 
there is a significant increase in the quantity of MBP protein harvested from the culture 
compared to vehicle control.
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(i) Tankyrase protein is expressed within OL lineage in human pediatric HIE white matter 
injury, where it is co-expressed within Olig2 positive cells, with NOGO-A+ and cytoplasmic 
Olig1+ cells, but separated from Iba1+ macrophages/microglia and GFAP+ astrocytes. Scale 
bar in i = 10μm.
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Figure 6. XAV939 treatment increases myelination, myelination following hypoxia, and 
remyelination in ex vivo mouse cerebellar slice cultures
(a) XAV939 promotes developmental myelination. Axons (NFH) are shown in red, myelin 
(MBP) shown in green, and paranodes showing compacted myelin sheaths (Caspr) are 
shown in white.
(a’) Quantification of myelination using a ratio of percent area stained for Caspr to percent 
area stained for NFH. Values shown are mean + SD, and the data were analyzed by one-way 
ANOVA with Dunnett’s multiple comparison test, and significant differences (**p<0.01, 
***p<0.001) are shown. Three independent experiments were conducted.
(b) XAV939 promotes myelination and recovery following acute hypoxic insult. Axons 
(NFH) are shown in red, myelin (MBP) shown in green, and paranodes showing compacted 
myelin sheaths (Caspr) are shown in white.
(b’) Acute hypoxia impedes differentiation of OLP in cerebellar slice cultures. Values 
shown are mean + SD, and the data were analyzed by unpaired t-test, and the significant 
difference (***p<0.001) is shown.
(c) XAV939 promotes remyelination following demyelination by lysolecithin. Axons (NFH) 
are shown in red, myelin (MBP) shown in green, and paranodes showing compacted myelin 
sheaths (Caspr) are shown in white. Scale bar: 50μm MBP/NFH and 25μm in Caspr panels.
(c’) Quantification of remyelination using a ratio of percent area stained for Caspr to percent 
area stained for NFH. Values shown are mean +/− SD, and the data were analyzed by one-
way ANOVA with Dunnett’s multiple comparison test, and the significant difference 
(***p<0.001) is shown. Three independent experiments were conducted per condition tested 
and 5-10 separate slices were counted per experiment.
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Figure 7. XAV939 treatment dramatically accelerates OLP differentiation and myelin 
regeneration during remyelination in vivo
(a) Injection of 0.1μM XAV939 into demyelinated lesions in young adult mouse spinal cord 
at the time of lysolecithin injection produces significant increases in the appearance of PLP 
mRNA expressing mature OL at 6dpl in dorsal or ventral funicular lesions compared to 
vehicle treated controls.
(b) XAV939 effects are Axin2-dependent, as Axin2 null mice show significantly less OLP 
differentiation at 6dpl following XAV+lysolecithin treatment versus controls.
(c) Quantification of (a) and (b) above at 6dpl during remyelination showing number of PLP 
mRNA expressing cells per mm2 after respective treatments.
(d, e) Whilst total Olig2+ OL lineage numbers were similar at 6dpl in XAV939 treated 
lesions and controls, XAV939 produced a shift in the proportion of mature PLP+ OL versus 
immature Nkx2.2+ OLP, with a significant increase (t test p=0.002, n=4) in mature OL.
(f) XAV939 treatment did not affect the astrocyte (GFAP) or macrophage (Iba1) infiltration 
into lesions at 6dpl.
(g) XAV939 treatment in lesions was not cytoprotective to existing mature OL, as there 
were no PLP-expressing cells at 3dpl within lesions of either group.
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(h, i) The OLP recruitment into lesions and proliferation phase at 3dpl were unaffected by 
XAV939 treatment, evidenced by similar numbers of Olig2+ cells in the lesion, a similar 
proportion of which were Ki67+. Scale bar in a, b, d, f, g, h = 50μm.
(j) The accelerated OLP differentiation produced by XAV939 treatment in lesions leads to 
an accelerated myelin regeneration at 10dpl, evidenced by significant increases in the 
thickness of restored myelin sheaths. G ratios were significantly different (t test p<0.0001) 
between control group (G ratio mean= 0.94, SEM 0.003) and XAV939-treated (G ratio 
mean= 0.90, SEM 0.004). Scale bar in j = 2μm.
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